Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bausch Health Companies (BHC) stocks in Canada

Learn how to easily invest in Bausch Health Companies stocks.

Bausch Health Companies is a drug manufacturers-specialty & generic business based in the US. Bausch Health Companies stocks (BHC.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $30.89 – a decrease of 4.37% over the previous week. Bausch Health Companies employs 21,600 staff and has a trailing 12-month revenue of around $8.5 billion.

How to buy shares in Bausch Health Companies

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BHC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Bausch Health Companies stock price (NYSE:BHC)

Use our graph to track the performance of BHC stocks over time.

Bausch Health Companies shares at a glance

Information last updated 2022-01-16.
Latest market close$25.58
52-week range$22.99 - $34.80
50-day moving average $26.22
200-day moving average $28.38
Wall St. target price$43.08
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.27

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Bausch Health Companies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Bausch Health Companies price performance over time

Historical closes compared with the close of $25.58 from 2022-01-19

1 week (2022-01-13) -4.37%
1 month (2021-12-20) -0.47%
3 months (2021-10-16) N/A
6 months (2021-07-20) -9.87%
1 year (2021-01-20) -5.29%
2 years (2020-01-17) -15.44%
3 years (2019-01-18) 10.78%
5 years (2017-01-20) 73.66%

Is Bausch Health Companies under- or over-valued?

Valuing Bausch Health Companies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bausch Health Companies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bausch Health Companies's EBITDA

Bausch Health Companies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 billion.

The EBITDA is a measure of a Bausch Health Companies's overall financial performance and is widely used to measure a its profitability.

Bausch Health Companies financials

Revenue TTM $8.5 billion
Operating margin TTM 19.65%
Gross profit TTM $5.8 billion
Return on assets TTM 3.41%
Return on equity TTM -446.54%
Profit margin -13.85%
Book value $1.51
Market capitalisation $9.7 billion

TTM: trailing 12 months

Bausch Health Companies's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bausch Health Companies.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Bausch Health Companies's total ESG risk score

Total ESG risk: 41.19

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bausch Health Companies's overall score of 41.19 (as at 12/31/2018) is pretty weak – landing it in it in the 89th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Bausch Health Companies is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Bausch Health Companies's environmental score

Environmental score: 3.36/100

Bausch Health Companies's environmental score of 3.36 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bausch Health Companies is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Bausch Health Companies's social score

Social score: 23.99/100

Bausch Health Companies's social score of 23.99 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bausch Health Companies is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Bausch Health Companies's governance score

Governance score: 16.84/100

Bausch Health Companies's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bausch Health Companies is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Bausch Health Companies's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Bausch Health Companies scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Bausch Health Companies has a damaged public profile.

Bausch Health Companies share dividends

We're not expecting Bausch Health Companies to pay a dividend over the next 12 months.

Have Bausch Health Companies's shares ever split?

Bausch Health Companies's shares were split on a 2:1 basis on 15 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bausch Health Companies shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bausch Health Companies shares which in turn could have impacted Bausch Health Companies's share price.

Bausch Health Companies share price volatility

Over the last 12 months, Bausch Health Companies's shares have ranged in value from as little as $22.99 up to $34.8. A popular way to gauge a stock's volatility is its "beta".

BHC.US volatility(beta: 1.64)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bausch Health Companies's is 1.6361. This would suggest that Bausch Health Companies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bausch Health Companies overview

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site